Royalty Pharma PLC
NASDAQ:RPRX
Royalty Pharma PLC
NASDAQ:RPRX
Price:
28.28 USD
-1.67%
Updated:
May 3, 2024
Royalty Pharma PLC
Cash from Financing Activities
|
Royalty Pharma PLC
Cash from Financing Activities Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Royalty Pharma PLC
NASDAQ:RPRX
|
Cash from Financing Activities
-$2.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Financing Activities
-$15.8B
|
CAGR 3-Years
-32%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Financing Activities
$8.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Financing Activities
$26.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Financing Activities
-$4.8B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
17%
|
CAGR 10-Years
-5%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Financing Activities
$3.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Royalty Pharma PLC's Cash from Financing Activities?
Cash from Financing Activities
-2.1B
USD
-2.1B
USD
Based on the financial report for Dec 31, 2023, Royalty Pharma PLC's Cash from Financing Activities amounts to -2.1B USD.
What is Royalty Pharma PLC's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-9%
-9%
Over the last year, the Cash from Financing Activities growth was -127%.
You don't have any saved screeners yet
